Prudent Man Advisors, LLC Incyte Corp Transaction History

Prudent Man Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$57.77 - $65.93 $11,091 - $12,658	-192 Reduced 2.81%	6,641 $383,000
Q2 2023 Aug 10, 2023	SELL	$60.95 - $75.51 $2,498 - $3,095	-41 Reduced 0.6%	6,833 $425,000
Q1 2023 May 05, 2023	SELL	$70.23 - $86.01 $702 - $860	-10 Reduced 0.15%	6,874 $497,000
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $137,383 - $172,004	2,045 Added 42.26%	6,884 $553,000
Q3 2022 Nov 09, 2022	BUY	$66.18 - $82.86 $1,455 - $1,822	22 Added 0.46%	4,839 $322,000
Q2 2022 Aug 05, 2022	SELL	$66.18 - $83.18 $2,051 - $2,578	-31 Reduced 0.64%	4,817 $366,000
Q1 2022 May 09, 2022	SELL	$66.02 - $79.71 $7,856 - $9,485	-119 Reduced 2.4%	4,848 $385,000
Q4 2021 Feb 10, 2022	SELL	$63.34 - $74.11 $380 - $444	-6 Reduced 0.12%	4,967 $365,000
Q3 2021 Nov 10, 2021	BUY	$68.67 - $84.02 $1,442 - $1,764	21 Added 0.42%	4,973 $342,000
Q2 2021 Aug 03, 2021	BUY	$79.87 - $87.53 $395,516 - $433,448	4,952 New	4,952 $417,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Prudent Man Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Prudent Man Advisors, LLC with notifications on news.